| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 34,542 | $0.12 | 51,625 | |
| May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 34,542 | $2.77 | 69,125 | |
| May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 34,542 | $0.12 | 69,125 | |
| December 5, 2012 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 34,583 | $3.25 | 156,625 | |
| December 5, 2012 | Director | Form 4 | Exercise of in-the-money or at-the-money derivative security | 34,583 | $3.25 | -- | |
| March 23, 2011 | Director | Form 4 | Conversion of derivative security | 34,583 | $2.40 | 34,583 | |
| January 14, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 34,583 | -- | 34,583 | |
| October 3, 2019 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 384,951 | |
| February 21, 2017 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 35,000 | $0.23 | 180,081 | |
| June 20, 2014 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 75,000 | |
| May 6, 2013 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 205,000 | |
| May 6, 2013 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 90,000 | |
| May 6, 2013 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 130,000 | |
| May 6, 2013 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 105,000 | |
| September 20, 2012 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 35,000 | $2.72 | 296,025 | |
| September 20, 2012 | Director | Form 4 | Exercise of in-the-money or at-the-money derivative security | 35,000 | $2.72 | 219,911 | |
| February 22, 2012 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 254,911 | |
| February 19, 2010 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | $2.94 | 169,911 | |
| March 22, 2007 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 35,000 | -- | 64,912 | |
| June 15, 2012 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 36,250 | $2.15 | 305,000 | |
| June 15, 2012 | SVP - IR/PR | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 36,250 | $2.15 | 245,000 | |
| June 15, 2012 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 36,250 | $2.15 | 282,009 | |
| March 19, 2013 | CFO | Form 4 | Open market or private sale of non-derivative or derivative security | 37,272 | $1.06 | -- | |
| March 17, 2015 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 37,500 | -- | 112,500 | |
| March 17, 2023 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 85,688 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
